CA3041554A1 - Reparation homologue de matrice massivement multiplexee pour remplacer le genome entier - Google Patents
Reparation homologue de matrice massivement multiplexee pour remplacer le genome entier Download PDFInfo
- Publication number
- CA3041554A1 CA3041554A1 CA3041554A CA3041554A CA3041554A1 CA 3041554 A1 CA3041554 A1 CA 3041554A1 CA 3041554 A CA3041554 A CA 3041554A CA 3041554 A CA3041554 A CA 3041554A CA 3041554 A1 CA3041554 A1 CA 3041554A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- organism
- dna sequence
- targeted nuclease
- whole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008439 repair process Effects 0.000 title claims abstract description 174
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 231
- 238000000034 method Methods 0.000 claims abstract description 151
- 238000011282 treatment Methods 0.000 claims abstract description 47
- 210000004602 germ cell Anatomy 0.000 claims abstract description 43
- 230000008859 change Effects 0.000 claims abstract description 42
- 239000000463 material Substances 0.000 claims abstract description 39
- 230000002068 genetic effect Effects 0.000 claims abstract description 15
- 101710163270 Nuclease Proteins 0.000 claims description 131
- 230000027455 binding Effects 0.000 claims description 90
- 239000002773 nucleotide Substances 0.000 claims description 87
- 125000003729 nucleotide group Chemical group 0.000 claims description 87
- 210000004027 cell Anatomy 0.000 claims description 69
- 230000008569 process Effects 0.000 claims description 59
- 230000008685 targeting Effects 0.000 claims description 55
- 239000003795 chemical substances by application Substances 0.000 claims description 38
- 238000005520 cutting process Methods 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 21
- 231100000219 mutagenic Toxicity 0.000 claims description 19
- 230000003505 mutagenic effect Effects 0.000 claims description 19
- 230000007246 mechanism Effects 0.000 claims description 18
- 238000012163 sequencing technique Methods 0.000 claims description 18
- 230000009471 action Effects 0.000 claims description 16
- 150000007523 nucleic acids Chemical group 0.000 claims description 13
- 230000009437 off-target effect Effects 0.000 claims description 13
- 238000012805 post-processing Methods 0.000 claims description 12
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000009826 distribution Methods 0.000 claims description 4
- 230000037406 food intake Effects 0.000 claims description 4
- 230000005847 immunogenicity Effects 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 102000053602 DNA Human genes 0.000 description 87
- 108020004414 DNA Proteins 0.000 description 87
- 230000035772 mutation Effects 0.000 description 29
- 238000002703 mutagenesis Methods 0.000 description 21
- 231100000350 mutagenesis Toxicity 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 108091033409 CRISPR Proteins 0.000 description 13
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000006801 homologous recombination Effects 0.000 description 9
- 238000002744 homologous recombination Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 241000702421 Dependoparvovirus Species 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 229920002477 rna polymer Polymers 0.000 description 8
- 241000193996 Streptococcus pyogenes Species 0.000 description 6
- 108091028113 Trans-activating crRNA Proteins 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108010042407 Endonucleases Proteins 0.000 description 5
- 102000004533 Endonucleases Human genes 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000005783 single-strand break Effects 0.000 description 5
- 206010012559 Developmental delay Diseases 0.000 description 4
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 4
- 108091093105 Nuclear DNA Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000005782 double-strand break Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 208000028060 Albright disease Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 201000000046 Beckwith-Wiedemann syndrome Diseases 0.000 description 3
- 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 3
- 208000000088 Enchondromatosis Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000007031 Incontinentia pigmenti Diseases 0.000 description 3
- 206010048911 Lissencephaly Diseases 0.000 description 3
- 201000002880 Maffucci syndrome Diseases 0.000 description 3
- 201000001853 McCune-Albright syndrome Diseases 0.000 description 3
- 208000009905 Neurofibromatoses Diseases 0.000 description 3
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 3
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 3
- 208000007531 Proteus syndrome Diseases 0.000 description 3
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 208000003119 hemimegalencephaly Diseases 0.000 description 3
- 208000014817 lissencephaly spectrum disease Diseases 0.000 description 3
- 201000004931 neurofibromatosis Diseases 0.000 description 3
- 230000006780 non-homologous end joining Effects 0.000 description 3
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 208000001061 polyostotic fibrous dysplasia Diseases 0.000 description 3
- 230000008263 repair mechanism Effects 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000033590 base-excision repair Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091079001 CRISPR RNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Theoretical Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Evolutionary Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des systèmes et des procédés de remplacement du génome entier par l'intermédiaire d'un processus de réparation homologue de matrice massivement multiplexé. Selon certains aspects, l'invention comprend un procédé de remplacement sensible de la séquence d'ADN d'un organisme, le procédé comprenant une ou plusieurs des étapes suivantes : la détermination d'une séquence d'ADN souhaitée, la séquence d'ADN souhaitée étant la séquence d'ADN par laquelle il est souhaitable que la séquence d'ADN de l'organisme soit sensiblement remplacée ; la préparation d'un traitement conçu pour amener la séquence d'ADN de l'organisme à être sensiblement remplacée par la séquence d'ADN souhaitée ; l'application du traitement à l'organisme où le traitement est conçu pour amener la séquence d'ADN de l'organisme à être sensiblement remplacée par la séquence d'ADN souhaitée par remplacement sensible, à chacun des multiples sites de la séquence d'ADN de l'organisme, du code génétique du site devant être sensiblement remplacé par le code génétique d'un site correspondant dans la séquence d'ADN souhaitée où chacun des multiples sites dans la séquence d'ADN de l'organisme est une sous-séquence respective de la séquence d'ADN de l'organisme et où l'application du traitement consiste à administrer à l'organisme au moins une dose, chaque dose comprenant un matériel de type agent de remplacement respectif qui provoque le remplacement du code génétique à une pluralité respective desdits multiples sites. Dans certains modes de réalisation, la séquence d'ADN de l'organisme est une séquence d'ADN du génome entier de l'organisme, et la séquence d'ADN souhaitée est sensiblement la séquence d'ADN du génome entier de la lignée germinale de l'organisme, une version intentionnellement modifiée de la séquence d'ADN du génome entier de la lignée germinale de l'organisme, ou une séquence d'ADN du génome entier d'un autre organisme.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662424195P | 2016-11-18 | 2016-11-18 | |
| US62/424,195 | 2016-11-18 | ||
| US62/567,744 | 2017-03-10 | ||
| US201762508259P | 2017-05-18 | 2017-05-18 | |
| US62/508,259 | 2017-05-18 | ||
| US201762554738P | 2017-09-06 | 2017-09-06 | |
| US62/554,738 | 2017-09-06 | ||
| US201762567744P | 2017-10-03 | 2017-10-03 | |
| PCT/US2017/062430 WO2018094291A1 (fr) | 2016-11-18 | 2017-11-17 | Réparation homologue de matrice massivement multiplexée pour remplacer le génome entier |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3041554A1 true CA3041554A1 (fr) | 2018-05-24 |
Family
ID=62145813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3041554A Pending CA3041554A1 (fr) | 2016-11-18 | 2017-11-17 | Reparation homologue de matrice massivement multiplexee pour remplacer le genome entier |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3541937A4 (fr) |
| AU (1) | AU2017362513A1 (fr) |
| CA (1) | CA3041554A1 (fr) |
| WO (1) | WO2018094291A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3067382A1 (fr) | 2017-06-15 | 2018-12-20 | The Regents Of The University Of California | Insertions ciblees d'adn non viral |
| SG11202003798TA (en) | 2017-10-27 | 2020-05-28 | Univ California | Targeted replacement of endogenous t cell receptors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111647627A (zh) * | 2014-04-28 | 2020-09-11 | 重组股份有限公司 | 多重基因编辑 |
-
2017
- 2017-11-17 WO PCT/US2017/062430 patent/WO2018094291A1/fr unknown
- 2017-11-17 AU AU2017362513A patent/AU2017362513A1/en active Pending
- 2017-11-17 EP EP17871613.0A patent/EP3541937A4/fr active Pending
- 2017-11-17 CA CA3041554A patent/CA3041554A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017362513A1 (en) | 2019-05-16 |
| WO2018094291A1 (fr) | 2018-05-24 |
| EP3541937A1 (fr) | 2019-09-25 |
| EP3541937A4 (fr) | 2020-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108463211B (zh) | 用于治疗肌联蛋白类肌病和其它肌联蛋白病变的材料和方法 | |
| Hodges et al. | Delivering on the promise of gene editing for cystic fibrosis | |
| GB2601617A (en) | Methods and compositions for editing nucleotide sequences | |
| IL288263B (en) | CRISPR DNA/RNA hybrid polynucleotides and methods of using them | |
| US20220080055A9 (en) | Compositions and methods for gene editing for hemophilia a | |
| US11491208B2 (en) | Sequence-specific in vivo cell targeting | |
| CN107922949A (zh) | 用于通过同源重组的基于crispr/cas的基因组编辑的化合物和方法 | |
| WO2015148860A1 (fr) | Méthodes et compositions liées à crispr/cas pour traiter la bêta-thalassémie | |
| Wu et al. | Allele-specific genome targeting in the development of precision medicine | |
| Ke et al. | Intronic motif pairs cooperate across exons to promote pre-mRNA splicing | |
| WO2019204668A1 (fr) | Compositions et procédés d'inactivation de l'apo (a) par édition génique pour le traitement d'une maladie cardiovasculaire | |
| CA3041554A1 (fr) | Reparation homologue de matrice massivement multiplexee pour remplacer le genome entier | |
| Kumar et al. | RNA-targeting strategies as a platform for ocular gene therapy | |
| US20130217585A1 (en) | Quantitative Total Definition of Biologically Active Sequence Elements | |
| AU2020221355A1 (en) | Compositions and methods for treating glycogen storage disease type 1a | |
| US20190338272A1 (en) | Massively multiplexed homologous template repair for whole-genome replacement | |
| KR20210113393A (ko) | 혈액응고인자 viii 유전자 역위 보정에 의한 혈우병 치료용 조성물 | |
| EP3690046A2 (fr) | Composition pour le traitement de l'hémophilie, comprenant un système crispr/cas ayant un potentiel de correction d'inversion du gène du facteur viii de coagulation | |
| Yin et al. | Recent advances in CRISPR-Cas system for the treatment of genetic hearing loss | |
| Lal et al. | Curative Therapy of Sickle Cell Disease Using Gene Editing Technologies | |
| AU2022201166B2 (en) | Type ii crispr/cas9 genome editing system and the application thereof | |
| WO2023115028A1 (fr) | Intervention contre le cancer en ciblant les différences génotypiques à l'aide de l'édition par délétion médiée par crispr-cas3 | |
| JP7422128B2 (ja) | 配列特異的なインビボ細胞標的化 | |
| WO2023169482A1 (fr) | Système d'édition génique modifié reposant sur la protéine crispr et procédés d'utilisation | |
| US20200009180A1 (en) | Methods of treating alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220518 |
|
| EEER | Examination request |
Effective date: 20220518 |
|
| EEER | Examination request |
Effective date: 20220518 |
|
| EEER | Examination request |
Effective date: 20220518 |
|
| EEER | Examination request |
Effective date: 20220518 |